Trial Outcomes & Findings for Allopurinol Add-on Treatment for Refractory Mania (NCT NCT00643123)
NCT ID: NCT00643123
Last Updated: 2019-05-08
Results Overview
The YMRS is an 11-item, clinician-administered rating scale to assess the severity of manic symptoms before, during and after treatment. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. A score of 0 indicates the behavior is absent, whereas a score of 4 or 8 indicates the behavior is present and severe. The change in score between Baseline and the Completion Visit will be reported. Ideally, the two time points will be Baseline and 6 Weeks after Baseline, but, if a subject terminates early, his/her last YMRS score will be carried forward to the final visit. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. A score of 0-12 indicates the absence of mania or a very mild manic state, a score of 13-20 or higher indicates a mild man
COMPLETED
PHASE4
40 participants
7 weeks (Baseline and 6 weeks (or last visit date) after baseline
2019-05-08
Participant Flow
8 subjects screen failed; 5 subjects did not qualify at Baseline. 13 total subjects were not randomized
Participant milestones
| Measure |
Allopurinol
Allopurinol: 300-600 mg/day over a 6 week period
|
Placebo
Placebo: Inactive substance
|
|---|---|---|
|
Overall Study
STARTED
|
15
|
12
|
|
Overall Study
COMPLETED
|
10
|
11
|
|
Overall Study
NOT COMPLETED
|
5
|
1
|
Reasons for withdrawal
| Measure |
Allopurinol
Allopurinol: 300-600 mg/day over a 6 week period
|
Placebo
Placebo: Inactive substance
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
4
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
Baseline Characteristics
Allopurinol Add-on Treatment for Refractory Mania
Baseline characteristics by cohort
| Measure |
Allopurinol
n=15 Participants
Allopurinol: 300-600 mg/day over a 6 week period
|
Placebo
n=12 Participants
Placebo: Inactive substance
|
Total
n=27 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
15 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
27 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
13 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race or Ethnicity · Caucasian
|
9 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race or Ethnicity · African-American
|
3 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race or Ethnicity · Hispanic
|
3 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
15 participants
n=99 Participants
|
12 participants
n=107 Participants
|
27 participants
n=206 Participants
|
|
Marital Status
Never Married
|
8 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
|
Marital Status
Married
|
1 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Marital Status
Divorced
|
4 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Marital Status
Not Reported
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Employment Status
Employed
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Employment Status
Unemployed
|
9 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
|
Employment Status
Disabled
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Employment Status
Student
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 7 weeks (Baseline and 6 weeks (or last visit date) after baselinePopulation: 27 subjects were randomized but 4 (3 from the Treatment group and 1 from the Control group) withdrew from the study immediately following the baseline visit. Therefore, a second time point was unavailable for these subjects.
The YMRS is an 11-item, clinician-administered rating scale to assess the severity of manic symptoms before, during and after treatment. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. A score of 0 indicates the behavior is absent, whereas a score of 4 or 8 indicates the behavior is present and severe. The change in score between Baseline and the Completion Visit will be reported. Ideally, the two time points will be Baseline and 6 Weeks after Baseline, but, if a subject terminates early, his/her last YMRS score will be carried forward to the final visit. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. A score of 0-12 indicates the absence of mania or a very mild manic state, a score of 13-20 or higher indicates a mild man
Outcome measures
| Measure |
Allopurinol
n=12 Participants
Allopurinol: 300-600 mg/day over a 6 week period
|
Placebo
n=11 Participants
Placebo: Inactive substance
|
|---|---|---|
|
Young Mania Rating Scale (YMRS)
|
-12.3 units on a scale
Standard Error 1.9
|
-9.6 units on a scale
Standard Error 2.7
|
SECONDARY outcome
Timeframe: 7 weeksPopulation: No data displayed because no data was collected prior to closing of the research unit.
The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of depression before, during, and after treatment. A 28-item HAM-D form was used but only the first 17 questions are used in the assessment for depression. Of the first 17 questions, eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The sum of the scores from the first 17 questions is: 0-7 = normal, 8-13 = mild depression, 14-18 = moderate depression, 19-22=severe depression and ≥ 23=very severe depression. Questions 18-28 are scored similarly and assess sleep disorders, paranoid behavior, motor dysfunction, psychosis, and weight gain, etc.
Outcome measures
Outcome data not reported
Adverse Events
Placebo
Allopurinol
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebo
n=12 participants at risk
Placebo: Inactive substance
|
Allopurinol
n=15 participants at risk
Allopurinol: 300-600 mg/day over a 6 week period
|
|---|---|---|
|
Psychiatric disorders
Suicidal thoughts and plan
|
0.00%
0/12 • 5 months
|
6.7%
1/15 • Number of events 1 • 5 months
|
|
Psychiatric disorders
Medication non-compliance
|
0.00%
0/12 • 5 months
|
6.7%
1/15 • Number of events 1 • 5 months
|
|
Reproductive system and breast disorders
Inflamed prostate
|
8.3%
1/12 • Number of events 1 • 5 months
|
0.00%
0/15 • 5 months
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place